Q2 Earnings Estimate for EPRX Issued By HC Wainwright

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for shares of Eupraxia Pharmaceuticals in a report released on Tuesday, March 17th. HC Wainwright analyst B. Folkes anticipates that the company will post earnings per share of ($0.20) for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ Q4 2026 earnings at ($0.21) EPS and FY2030 earnings at $0.17 EPS.

A number of other research analysts have also commented on EPRX. Lifesci Capital upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Cantor Fitzgerald boosted their target price on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research report on Thursday, January 15th. Wall Street Zen cut Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Eupraxia Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $15.00.

Eupraxia Pharmaceuticals Trading Up 2.6%

Eupraxia Pharmaceuticals stock opened at $7.58 on Wednesday. Eupraxia Pharmaceuticals has a 1-year low of $2.68 and a 1-year high of $9.32. The firm has a market capitalization of $272.58 million, a PE ratio of -7.36 and a beta of 1.27. The firm’s 50 day simple moving average is $8.29 and its 200 day simple moving average is $6.87.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21).

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Quadrature Capital Ltd bought a new stake in Eupraxia Pharmaceuticals in the second quarter worth $61,000. TCI Wealth Advisors Inc. bought a new stake in shares of Eupraxia Pharmaceuticals in the 3rd quarter valued at about $65,000. Integrated Wealth Concepts LLC purchased a new stake in Eupraxia Pharmaceuticals during the 3rd quarter valued at about $71,000. Bank of America Corp DE grew its position in Eupraxia Pharmaceuticals by 402.4% during the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after acquiring an additional 10,059 shares during the last quarter. Finally, Guardian Wealth Advisors LLC NC purchased a new position in Eupraxia Pharmaceuticals in the 4th quarter worth approximately $76,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.